ENTITY
Shenzhen Hepalink Pharmaceutical

Shenzhen Hepalink Pharmaceutical (9989 HK)

97
Analysis
Health Care • China
Shenzhen Hepalink Pharmaceutical is a multinational biopharmaceutical company with core businesses in the heparin industrial chain, large molecule biologics CDMO services, and the research, development, and commercialization of innovative drugs. Its key products include heparin sodium APIs and enoxaparin sodium preparations. The company is headquartered in Shenzhen, China, and was founded in 1998.
more
•16 Jan 2022 12:29

A/H Premium Weekly: Biggest A/H Premium Declines in a Year

The market average A/H premium registered the biggest declines in the past one year. We highlight top sectors by the decline of A/H premium, as...

Logo
430 Views
Share
•31 Dec 2021 18:33

A/H Premium Weekly: Industrials Led Premium Increase

Top three sectors in terms of A/H premium increase were consumer stable, utilities and industrials. Six industrial names appeared in the top 10 A/H...

Logo
710 Views
Share
•17 Dec 2021 17:08

A/H Premium Weekly: Health Care A/H Premium at 52W High

We highlight that  A/H premium of Health Care sector at 52 week high due to rumor of entity list inclusion, this is due to A/H premia of many...

Logo
572 Views
Share
•20 Mar 2021 23:59

Quiddity Weekly H/A: Consumer Strong, Spreads Narrowing Masks A-Share Weakness

The move in H/A spreads was 96bp this week. The strength in spreads masks some A-share weakness in the big and liquid names. Quiddity long/short...

Logo
599 Views
Share
x